CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer.

ABSTRACT: The success of PD-1/PD-L1-targeted therapy in lung cancer has resulted in great enthusiasm for additional immunotherapies in development to elicit similar survival benefits, particularly in patients who do not respond to or are ineligible for PD-1 blockade. CD47 is an immunosuppressive molecule that binds SIRPα on antigen-presenting cells to regulate an innate immune checkpoint that blocks phagocytosis and subsequent activation of adaptive tumor immunity. In lung cancer, CD47 expression is associated with poor survival and tumors with EGFR mutations, which do not typically respond to PD-1 blockade. Given its prognostic relevance, its role in facilitating immune escape, and the number of agents currently in clinical development, CD47 blockade represents a promising next-generation immunothe

SUBMITTER: Lau APY 

PROVIDER: S-EPMC10649163 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature